Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;2(9):e424.
doi: 10.1016/S2666-5247(21)00189-0. Epub 2021 Jul 28.

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19

Grégory Destras  1   2 , Souad Assaad  3 , Antonin Bal  1 , Maude Bouscambert-Duchamp  1 , Virginie Avrillon  3 , Bruno Simon  1 , Martine Valette  1   2 , Jean-Yves Blay  3 , Bruno Lina  1   2 , Emilie Frobert  1   2 , Laurence Josset  1   2
Affiliations

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19

Grégory Destras et al. Lancet Microbe. 2021 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. BL is a member of the French Scientific Committee for SARS-CoV-2. We thank laboratory technicians and Quentin Semanas for their active participation and help with this study. This study was done as part of the global surveillance of influenza viruses by WHO and by the Centre National de Référence des Virus des Infections Respiratoires, supported by Santé Publique France in France. Patients were included in a temporary authorisation for use cohort for bamlanivimab infusion with unique authorisation (AU-041) for data collection and data sharing and including patient informed consent. Investigations were done in accordance with the General Data Protection Regulation (Regulation [EU] 2016/679 and Directive 95/46/EC) and French data protection law (Law 78–17 on Jan 6, 1978, and Décret 2019–536 on May 29, 2019).

References

    1. Gottlieb RL, Nirula A, Chen P. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–644. - PMC - PubMed
    1. Chen P, Nirula A, Heller B. SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med. 2021;384:229–237. - PMC - PubMed
    1. Choi B, Choudhary MC, Regan J. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291–2293. - PMC - PubMed
    1. Hoffmann M, Arora P, Groß R. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384–2393. - PMC - PubMed
    1. Starr TN, Greaney AJ, Addetia A. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371:850–854. - PMC - PubMed

Publication types

Substances